Sanofi puts new CSO in Boston, adding more weight to U.S. R&D

Sanofi's ($SNY) center of gravity is continuing its shift toward the U.S. The French drugmaker not only recruited a top official at the National Institutes of Health to be its chief scientific officer. It also decided to place him in the Boston area, where it set up an R&D hub last year. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.